Fulcrum Therapeutics (FULC) Competitors $6.88 +0.36 (+5.52%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$6.88 +0.00 (+0.01%) As of 08/22/2025 05:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock FULC vs. ARDX, HROW, SPRY, SDGR, AMPH, VERA, ABCL, ETNB, SNDX, and COGTShould you be buying Fulcrum Therapeutics stock or one of its competitors? The main competitors of Fulcrum Therapeutics include Ardelyx (ARDX), Harrow (HROW), ARS Pharmaceuticals (SPRY), Schrodinger (SDGR), Amphastar Pharmaceuticals (AMPH), Vera Therapeutics (VERA), AbCellera Biologics (ABCL), 89BIO (ETNB), Syndax Pharmaceuticals (SNDX), and Cogent Biosciences (COGT). These companies are all part of the "pharmaceutical products" industry. Fulcrum Therapeutics vs. Its Competitors Ardelyx Harrow ARS Pharmaceuticals Schrodinger Amphastar Pharmaceuticals Vera Therapeutics AbCellera Biologics 89BIO Syndax Pharmaceuticals Cogent Biosciences Ardelyx (NASDAQ:ARDX) and Fulcrum Therapeutics (NASDAQ:FULC) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, media sentiment, valuation, earnings, dividends, analyst recommendations and risk. Is ARDX or FULC more profitable? Fulcrum Therapeutics has a net margin of 0.00% compared to Ardelyx's net margin of -14.60%. Fulcrum Therapeutics' return on equity of -31.05% beat Ardelyx's return on equity.Company Net Margins Return on Equity Return on Assets Ardelyx-14.60% -36.57% -13.42% Fulcrum Therapeutics N/A -31.05%-28.96% Which has stronger earnings & valuation, ARDX or FULC? Fulcrum Therapeutics has lower revenue, but higher earnings than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than Fulcrum Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArdelyx$333.61M4.41-$39.14M-$0.23-26.57Fulcrum Therapeutics$80M4.65-$9.73M-$1.22-5.64 Does the media refer more to ARDX or FULC? In the previous week, Ardelyx had 2 more articles in the media than Fulcrum Therapeutics. MarketBeat recorded 4 mentions for Ardelyx and 2 mentions for Fulcrum Therapeutics. Ardelyx's average media sentiment score of 1.21 beat Fulcrum Therapeutics' score of 0.96 indicating that Ardelyx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ardelyx 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fulcrum Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders hold more shares of ARDX or FULC? 58.9% of Ardelyx shares are owned by institutional investors. Comparatively, 89.8% of Fulcrum Therapeutics shares are owned by institutional investors. 4.8% of Ardelyx shares are owned by insiders. Comparatively, 7.0% of Fulcrum Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has more volatility and risk, ARDX or FULC? Ardelyx has a beta of 0.68, indicating that its stock price is 32% less volatile than the S&P 500. Comparatively, Fulcrum Therapeutics has a beta of 2.47, indicating that its stock price is 147% more volatile than the S&P 500. Do analysts prefer ARDX or FULC? Ardelyx currently has a consensus target price of $11.50, suggesting a potential upside of 88.22%. Fulcrum Therapeutics has a consensus target price of $7.57, suggesting a potential upside of 10.05%. Given Ardelyx's stronger consensus rating and higher possible upside, research analysts clearly believe Ardelyx is more favorable than Fulcrum Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ardelyx 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.00Fulcrum Therapeutics 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.63 SummaryArdelyx and Fulcrum Therapeutics tied by winning 8 of the 16 factors compared between the two stocks. Get Fulcrum Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FULC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FULC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FULC vs. The Competition Export to ExcelMetricFulcrum TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$372.15M$3.12B$5.83B$9.78BDividend YieldN/A2.23%4.40%4.05%P/E Ratio-5.6421.0031.3026.05Price / Sales4.65357.30455.25117.77Price / CashN/A44.5038.0259.36Price / Book1.748.129.536.60Net Income-$9.73M-$54.72M$3.26B$265.65M7 Day Performance0.88%2.62%2.14%2.01%1 Month Performance-13.02%2.68%2.81%-0.33%1 Year Performance-24.97%10.93%30.70%19.04% Fulcrum Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FULCFulcrum Therapeutics0.9437 of 5 stars$6.88+5.5%$7.57+10.0%-21.7%$372.15M$80M-5.64100ARDXArdelyx4.3051 of 5 stars$5.81-2.7%$11.50+97.9%+1.0%$1.44B$386.15M-25.2690Positive NewsHROWHarrow3.6232 of 5 stars$38.32-1.3%$64.67+68.8%-5.3%$1.44B$199.61M-153.28180Analyst RevisionSPRYARS Pharmaceuticals2.4671 of 5 stars$14.03-3.4%$31.00+121.0%+5.4%$1.44B$89.15M-28.6390Insider TradeSDGRSchrodinger3.1009 of 5 stars$20.05+3.5%$27.83+38.8%+4.3%$1.43B$207.54M-8.08790AMPHAmphastar Pharmaceuticals3.4626 of 5 stars$29.76-0.2%$31.50+5.8%-35.4%$1.39B$731.97M11.152,028Positive NewsVERAVera Therapeutics3.7329 of 5 stars$21.80+1.2%$63.00+189.0%-42.3%$1.37BN/A-6.0940Positive NewsABCLAbCellera Biologics2.0999 of 5 stars$4.67+1.7%$8.00+71.3%+74.9%$1.37B$28.83M-8.49500Gap UpETNB89BIO1.997 of 5 stars$9.44+2.3%$26.29+178.5%+11.3%$1.37BN/A-2.6140SNDXSyndax Pharmaceuticals4.0742 of 5 stars$15.87+0.8%$38.00+139.4%-20.1%$1.36B$77.93M-4.08110COGTCogent Biosciences3.6242 of 5 stars$12.11+1.9%$18.70+54.4%+24.7%$1.35BN/A-6.8080Positive News Related Companies and Tools Related Companies ARDX Competitors HROW Competitors SPRY Competitors SDGR Competitors AMPH Competitors VERA Competitors ABCL Competitors ETNB Competitors SNDX Competitors COGT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FULC) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fulcrum Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fulcrum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access